Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) Insider Sells 7,000 Shares of Company Stock

Key Points

• Insider sale: Joana Goncalves sold 7,000 Oruka Therapeutics shares for approximately $523,670 at an average price of $74.81 under a pre-arranged Rule 10b5-1 plan. Her remaining stake fell 18.05% to 31,771 shares.
• Stock performance: ORKA shares declined 3.7% to $73.87, below their 50-day moving average of $93.48 but above the 52-week low of $25.11. The company recently reported quarterly EPS of negative $0.55, missing estimates by $0.04.
• Analyst outlook: Despite one sell rating, 10 analysts rate the stock a Buy, resulting in a “Moderate Buy” consensus and an average price target of $128.91. Institutional investors own 56.44% of the company.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) insider Joana Goncalves sold 7,000 shares of the company's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the sale, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This trade represents a 18.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Tuesday, September 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86.
• On Monday, August 17th, Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $111.84, for a total value of $782,880.00.

Oruka Therapeutics Stock Down 3.7%

Shares of Oruka Therapeutics stock traded down $2.81 during trading on Thursday, reaching $73.87. The company's stock had a trading volume of 1,222,106 shares, compared to its average volume of 1,090,003. The firm's 50-day moving average is $93.48 and its two-hundred day moving average is $79.88. Oruka Therapeutics, Inc. has a 52-week low of $25.11 and a 52-week high of $115.51. The company has a market cap of $4.89 billion, a price-to-earnings ratio of -36.39 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.

Institutional Investors Weigh In On Oruka Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Nykredit A S purchased a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $29,000. GAMMA Investing LLC raised its position in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company's stock valued at $31,000 after purchasing an additional 250 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Oruka Therapeutics in the fourth quarter valued at about $67,000. Orion Capital Management LLC purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at approximately $91,000. Finally, Royal Bank of Canada lifted its holdings in shares of Oruka Therapeutics by 178.5% during the first quarter. Royal Bank of Canada now owns 3,172 shares of the company's stock worth $155,000 after purchasing an additional 2,033 shares during the period. 56.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ORKA shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Tuesday. HC Wainwright reiterated a "buy" rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. UBS Group boosted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Wedbush set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 24th. Finally, Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, September 3rd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $128.91.

About Oruka Therapeutics

Oruka Therapeutics, Inc NASDAQ: ORKA is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.